GLPG Galapagos NV

189.63
+0.86  (+0%)
Previous Close 188.77
Open 190.92
Price To Book 4.36
Market Cap 12,244,716,680
Shares 64,571,622
Volume 69,453
Short Ratio
Av. Daily Volume 129,405
Stock charts supplied by TradingView

NewsSee all news

  1. NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE

    -- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional Disease

  2. NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE

    -- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional Disease

  3. New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile

    -- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional

  4. Galapagos increases share capital through warrant exercise by Gilead

    Mechelen, Belgium; 6 November 2019, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announces a share capital increase arising from a warrant exercise by Gilead. On 1 November 2019,

  5. Galapagos increases share capital through warrant exercise by Gilead

    Mechelen, Belgium; 6 November 2019, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announces a share capital increase arising from a warrant exercise by Gilead. On 1 November 2019,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data lower than expectations released June 28, 2018.
GLPG2737 - PELICAN
Adult CF patients who are homozygous for the Class II F508del mutation
Phase 2 trial initiation announced July 5, 2017.
Filgotinib
Non-infectious uveitis
Phase 2b data due 2H 2020.
GLPG1972 - ROCCELLA
Osteoarthritis
Phase 2 trial did not meet primary endpoint.
Filgotinib and GS-9876
Cutaneous lupus erythematosus (CLE)
Phase 3 trial to be initiated 1H 2020.
Filgotinib - TORTUGA
Ankylosing spondylitis
Phase 3 trial to be initiated 4Q 2019.
Filgotinib
Psoriatic arthritis
Phase 2a postive top-line data released November 20, 2017.
GLPG2222 - ALBATROSS
Cystic fibrosis (CF)
Phase 2 top-line data released December 20, 2016.
GLPG1837
Cystic Fibrosis
Phase 3 trial initiation announced December 17, 2018.
ISABELA - GLPG1690
Idiopathic pulmonary fibrosis
Phase 3 data due 2Q 2020.
Filgotinib - SELECTION
Ulcerative colitis
Phase 3 enrolment to be completed 3Q 2020.
Filgotinib - DIVERSITY
Crohn’s disease
NDA filing due 4Q 2019.
Filgotinib
Rheumatoid arthritis (RA)
Phase 2 trial halted due to futility - October 28, 2019.
MOR106 IGUANA
Atopic dermatitis
Phase 2 enrolment to be completed in 2019.
GLPG1205 - PINTA
Idiopathic pulmonary fibrosis (IPF)
Phase 2 initiation announced January 7, 2019.
GLPG1690 - NOVESA
Systemic sclerosis
Phase 1 data due 2H 2019.
GLPG3312
Healthy volunteers
Phase 1 trial initiation announced September 24, 2019.
GLPG3970
Psoriasis

Latest News

  1. NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE

    -- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional Disease

  2. NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE

    -- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional Disease

  3. New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile

    -- Pooled Analysis from the FINCH RA Clinical Program with Investigational Filgotinib Reinforces Favorable Safety and Tolerability Profile Alone and in Combination with Methotrexate (MTX) or Conventional

  4. Galapagos increases share capital through warrant exercise by Gilead

    Mechelen, Belgium; 6 November 2019, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announces a share capital increase arising from a warrant exercise by Gilead. On 1 November 2019,

  5. Galapagos increases share capital through warrant exercise by Gilead

    Mechelen, Belgium; 6 November 2019, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announces a share capital increase arising from a warrant exercise by Gilead. On 1 November 2019,

  6. Gilead delivers exercise notice to Galapagos for Initial Warrant A to increase ownership to 25.1%

    Mechelen, Belgium; 1 November 2019; 21:01 CET – Gilead Therapeutics A1 Unlimited Company, an affiliate of Gilead Sciences, Inc. (NASDAQ:GILD), delivered an exercise notice to Galapagos NV ((Euronext &, NASDAQ:GLPG) in

  7. Gilead delivers exercise notice to Galapagos for Initial Warrant A to increase ownership to 25.1%

    Mechelen, Belgium; 1 November 2019; 21:01 CET – Gilead Therapeutics A1 Unlimited Company, an affiliate of Gilead Sciences, Inc. (NASDAQ:GILD), delivered an exercise notice to Galapagos NV ((Euronext &, NASDAQ:GLPG) in

  8. GILEAD AND GALAPAGOS TO PRESENT NEW DATA ON FILGOTINIB AT 2019 ACR/ARP ANNUAL MEETING

    New analyses from filgotinib clinical development program reinforce the investigational medicine's consistent efficacy and safety profile in the treatment of inflammatory diseases FOSTER CITY, Calif. and

  9. Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting

    New analyses from filgotinib clinical development program reinforce the investigational medicine's consistent efficacy and safety profile in the treatment of inflammatory diseases Gilead Sciences, Inc. (NASDAQ:GILD)

  10. GILEAD AND GALAPAGOS TO PRESENT NEW DATA ON FILGOTINIB AT 2019 ACR/ARP ANNUAL MEETING

    New analyses from filgotinib clinical development program reinforce the investigational medicine's consistent efficacy and safety profile in the treatment of inflammatory diseases FOSTER CITY, Calif. and

  11. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  12. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  13. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  14. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  15. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  16. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  17. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  18. MOR106 clinical development in atopic dermatitis stopped for futility

    20.15 CET; regulated information - MorphoSys AG ((FSE: MOR, Prime Standard Segment, TecDAX, NASDAQ:MOR) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the end of the clinical development program of MOR106

  19. Galapagos receives transparency notification from Wellington Management Group LLP

    Mechelen, Belgium; 25 October 2019; 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a new transparency notification from Wellington Management Group LLP. Pursuant to

  20. Galapagos receives transparency notification from Wellington Management Group LLP

    Mechelen, Belgium; 25 October 2019; 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a new transparency notification from Wellington Management Group LLP. Pursuant to

  21. Solid third quarter 2019 performance with strong balance sheet for continued R&D growth

    First nine month financial results: Group revenues of €752.5 millionOperating profit of €393.0 millionNet profit of €265.3 millionCash and cash equivalents on 30 Sept 2019 of €5.6 billion Established unique

  22. Solid third quarter 2019 performance with strong balance sheet for continued R&D growth

    First nine month financial results: Group revenues of €752.5 millionOperating profit of €393.0 millionNet profit of €265.3 millionCash and cash equivalents on 30 Sept 2019 of €5.6 billion Established unique

  23. Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis

    Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral,

  24. GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS

      Foster City, Calif. and Mechelen, Belgium; October 11, 2019, 0.00 CET; – Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that Week 52 data from the registrational

  25. GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS

      Foster City, Calif. and Mechelen, Belgium; October 11, 2019, 0.00 CET; – Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that Week 52 data from the registrational

  26. Galapagos receives transparency notification from Wellington Management Group LLP

    Mechelen, Belgium; 7 October 2019; 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Wellington Management Group LLP. Pursuant to

  27. Galapagos receives transparency notification from Wellington Management Group LLP

    Mechelen, Belgium; 7 October 2019; 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Wellington Management Group LLP. Pursuant to

  28. Galapagos initiates Phase 1 trial for second Toledo compound

    Second generation compound of novel target class with dual action in inflammatory disordersDiscovered and validated on Galapagos' target discovery platform Mechelen, Belgium; 24 September 2019, 22.01 CET – Galapagos

  29. Galapagos initiates Phase 1 trial for second Toledo compound

    Second generation compound of novel target class with dual action in inflammatory disordersDiscovered and validated on Galapagos' target discovery platform Mechelen, Belgium; 24 September 2019, 22.01 CET – Galapagos

  30. Invitation to the special and extraordinary shareholders' meetings

    Mechelen, Belgium; 20 September 2019, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) invites its shareholders to a special and extraordinary shareholders' meeting. On 14 July 2019,

  31. Invitation to the special and extraordinary shareholders' meetings

    Mechelen, Belgium; 20 September 2019, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) invites its shareholders to a special and extraordinary shareholders' meeting. On 14 July 2019,

  32. Transparency notification

    Mechelen, Belgium; 19 september 2019; 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Sands Capital Management, LLC. Pursuant to Belgian

  33. Galapagos increases share capital through warrant exercises

    Mechelen, Belgium; 19 September 2019, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announces a share capital increase arising from warrant exercises. Galapagos issued 301,745

  34. Galapagos increases share capital through warrant exercises

    Mechelen, Belgium; 19 September 2019, 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announces a share capital increase arising from warrant exercises. Galapagos issued 301,745

  35. Transparency notification

    Mechelen, Belgium; 30 August 2019; 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Van Herk Investments B.V. Pursuant to Belgian

  36. Transparency notification

    Mechelen, Belgium; 30 August 2019; 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Van Herk Investments B.V. Pursuant to Belgian

  37. Transparency notification – Gilead holds 22% of Galapagos shares

    Mechelen, Belgium; 28 August 2019; 22.01 CEST; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Gilead Sciences, Inc. Pursuant to Belgian

  38. Transparency notification – Gilead holds 22% of Galapagos shares

    Mechelen, Belgium; 28 August 2019; 22.01 CEST; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Gilead Sciences, Inc. Pursuant to Belgian